Trial reportEuropean journal of nuclear medicine and molecular imaging2019
Predicting locally advanced rectal cancer response to neoadjuvant therapy with
Trial report in European journal of nuclear medicine and molecular imaging, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 78 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
78 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- FDG-PET/MRI in colorectal cancer care: an updated systematic review.Abdominal radiology (New York) · 2025Pooled it
- Radiomics for Predicting Response of Neoadjuvant Chemotherapy in Nasopharyngeal Carcinoma: A Systematic Review and Meta-Analysis.Frontiers in oncology · 2022Pooled it
- Radiomic analysis for predicting prognosis of colorectal cancer from preoperativeJournal of translational medicine · 2022Trial
- Radiomic signature of the FOWARC trial predicts pathological response to neoadjuvant treatment in rectal cancer.Journal of translational medicine · 2021Trial
- Pretreatment Staging FDG PET-Derived Radiomic Score Predicts Progression-Free Survival in Locally Advanced Rectal Cancer Treated with Total Neoadjuvant Therapy.Diagnostics (Basel, Switzerland) · 2026Article
- Deep learning feature-based model on abdominal radiography outperforms experts for early necrotizing enterocolitis diagnosis in neonates.European radiology · 2026Article
- KRASCellular & molecular biology letters · 2026Article
- MRI-Based Radiomics to Predict Response to Neoadjuvant Therapy in Locally Advanced Rectal Cancer: A Retrospective Study.Journal of personalized medicine · 2026Article
- Radiomics-based model for predicting neoadjuvant therapy response in esophageal cancer: Limitations and suggestions.World journal of gastrointestinal oncology · 2026Article
- Clinical utility and future directions of FDG-PET in rectal cancer management.Annals of nuclear medicine · 2026Review
- Role of 18FDG PET-CT & MRI for Predicting Response to Neo-Adjuvant Therapy in Rectal Cancer.Journal of gastrointestinal cancer · 2025Article
- Article
- Predicting Human Epidermal Growth Factor Receptor 2 Expression in Breast Cancer Based on Radiomics of MRI Habitat and US.Breast cancer (Dove Medical Press) · 2025Article
- Radiomics and visual analysis for predicting success of transplantation of heterotopic glioblastoma in mice with MRI.Journal of neuro-oncology · 2024Article
- Article
- Multiparametric magnetic resonance imaging (MRI)-based radiomics model explained by the Shapley Additive exPlanations (SHAP) method for predicting complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a multicenter retrospective study.Quantitative imaging in medicine and surgery · 2024Article
- Comparison of conventional MRI analysis versus MRI-based radiomics to predict the circumferential margin resection involvement of rectal cancer.BMC gastroenterology · 2024Article
- Development and validation of a multi-modal ultrasomics model to predict response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer.BMC medical imaging · 2024Article
- An interpretable clinical ultrasound-radiomics combined model for diagnosis of stage I cervical cancer.Frontiers in oncology · 2024Article
- Radiomics in rectal cancer: current status of use and advances in research.Frontiers in oncology · 2024Review
18 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
purposePathological complete response (pCR) following neoadjuvant chemoradiotherapy or radiotherapy in locally advanced rectal cancer (LARC) is reached in approximately 15-30% of cases, therefore it would be useful to assess if pretreatment of
methodsFifty-two patients were dichotomized as responder (pR+) or non-responder (pR-) according to their pathological tumor regression grade (TRG) as follows: 22 as pR+ (nine with TRG = 1, 13 with TRG = 2) and 30 as pR- (16 with TRG = 3, 13 with TRG = 4 and 1 with TRG = 5). First-order parameters and 21 second-order texture parameters derived from the Gray-Level Co-Occurrence matrix were extracted from semi-automatically segmented tumors on T2w MRI, ADC maps, and PET/CT acquisitions. The role of each texture feature in predicting pR+ was assessed with monoparametric and multiparametric models.
resultsIn the mono-parametric approach, PET homogeneity reached the maximum AUC (0.77; sensitivity = 72.7% and specificity = 76.7%), while PET glycolytic volume and ADC dissimilarity reached the highest sensitivity (both 90.9%). In the multiparametric analysis, a logistic regression model containing six second-order texture features (five from PET and one from T2w MRI) yields the highest predictivity in distinguish between pR+ and pR- patients (AUC = 0.86; sensitivity = 86%, and specificity = 83% at the Youden index).
conclusionsIf preliminary results of this study are confirmed, pretreatment PET and MRI could be useful to personalize patient treatment, e.g., avoiding toxicity of neoadjuvant therapy in patients predicted pR-.
Indexed as
Identifiers
30637502What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.